Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 01-2025 | 10-2024 | 07-2024 | 04-2024 | 01-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,358 | 4,093 | 1,194 | 376 | 283 |
| TOTAL | $3,947 | $4,767 | $1,416 | $455 | $594 |
| Non-Current Assets | |||||
| PPE Net | 228 | 241 | 254 | 176 | 189 |
| TOTAL | $228 | $241 | $254 | $176 | $189 |
| Total Assets | $4,176 | $5,008 | $1,670 | $632 | $783 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 726 | 1,255 | 2,882 | 2,925 | 3,827 |
| TOTAL | $726 | $1,255 | $2,882 | $3,226 | $3,827 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1,220 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $1,220 |
| Total Liabilities | $726 | $1,255 | $2,882 | $3,226 | $5,047 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 733 | 604 | 432 | 93 | 76 |
| Common Shares | 1 | 1 | 0 | 0 | 1 |
| Retained earnings | -57,396 | -56,410 | -54,995 | -54,020 | -53,169 |
| Other shareholders' equity | 0 | 0 | 0 | 0 | -70 |
| TOTAL | $3,450 | $3,753 | $-1,212 | $-2,594 | $-4,264 |
| Total Liabilities And Equity | $4,176 | $5,008 | $1,670 | $632 | $783 |